Full-Time
Senior Accountant
Updated on 9/4/2026
Collegium Pharmaceutical
201-500 employees
Specialty biopharmaceuticals developing extended-release pain medications
Compensation Overview
$95k - $115k/yr
Boston, MA, USA
Hybrid
Three days on-site per week required. The headquarters will relocate from Stoughton to Boston in Q1 2027.
Bachelor's
 Accounting (1) |
|---|
Get referred to Collegium Pharmaceutical
See people who can refer or advise you
- A Bachelor's degree in Accounting is required.
- Two to four years of related experience is required.
- A strong understanding of generally accepted accounting principles is required.
- Experience effectively managing multiple priorities simultaneously and performing within deadlines is required.
- Hands-on experience using Microsoft Excel at an advanced level is required.
- Support the period close process by preparing reconciliations and journal entries, and assist in maintaining revenue recognition models, including gross-to-net accounting, ensuring ASC 606 compliance.
- Work closely with members of the accounting team to identify opportunities to improve the accuracy, timeliness, and effectiveness of financial reporting.
- Work closely with Commercial Finance, Market Access, Compliance, and Supply Chain teams to effectively record and report revenue, providing insights into how business activities impact financial results.
- Provide support to internal controls under the Sarbanes-Oxley Act and external financial reporting, including Securities and Exchange Commission reporting, as necessary.
- Build relationships with colleagues from functions including FP&A, Legal, Human Resources, Information Technology, Research and Development, Operations, and Sales and Marketing.
- Collaborate with external auditors during audits by providing necessary documentation and explanations.
- Communicate clearly with explanations and clarifying questions.
- Implement continuous improvements and solve routine problems.
- A Certified Public Accountant credential is preferred.
- Big Four public accounting experience in auditing is preferred.
- Experience auditing or working at or with pharmaceutical or biotechnology companies and/or gross-to-net revenue experience is preferred.
Preparing summary...
Company Size
201-500
Company Stage
IPO
Headquarters
Cumberland, Maryland
Founded
2002
Get referred to Collegium Pharmaceutical
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 JORNAY PM revenue rose 41% to $46.1 million.
- AZSTARYS contributed $12.9 million after May 12, 2026, and guidance rose.
- May 2026 acquisition targets $50 million-plus synergies within twelve months, supporting EBITDA.
What critics are saying
- Nucynta generic pricing cut 2026 product revenue guidance to $825 million-$855 million.
- Chief Commercial Officer Scott Dreyer leaves August 30, 2026, disrupting AZSTARYS integration.
- Failure to replace pain cash flows with ADHD growth threatens a leverage trap.
What makes Collegium Pharmaceutical unique
- JORNAY PM reached 30,000 prescribers by Q2 2026, driving ADHD franchise momentum.
- AZSTARYS added complementary ADHD coverage after Collegium's May 12, 2026 acquisition.
- Collegium owns six medicines spanning pain and CNS, reducing single-product dependence.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 11%1 year growth
↑ 0%2 year growth
↑ 12%Collegium Pharmaceutical reported strong second-quarter 2026 results, driven by significant growth in its ADHD business. The company's Jornay PM product generated $46.1 million in net revenue, up 41% year-over-year, with prescriptions growing 13.1%. The number of healthcare providers prescribing Jornay PM reached an all-time high of over 30,000 in the quarter, representing a 17.6% increase from the same period last year. Collegium completed the acquisition of Azstarys in May, adding a complementary ADHD treatment to its portfolio. The company now operates with six differentiated medicines across its CNS and pain treatment portfolio. Chief executive Vikram Karnani highlighted that the Azstarys acquisition reinforces the company's strategy, initiated in 2024, to diversify beyond pain management and strengthen its position in the growing ADHD market. The company maintains an established pain business alongside its expanding ADHD franchise.
Why is Collegium Pharmaceutical stock tumbling today? Published 08/06/2026, 09:15 AM (C) Reuters. Investing.com - Shares of Collegium Pharmaceutical fell 13.2% in pre-open trading after the specialty biopharmaceutical company reported second-quarter 2026 financial results before the market open and simultaneously trimmed its full-year revenue outlook. The company posted net revenues of $199.9 million for the quarter, a 6.3% increase from the same period a year earlier, but the figure fell short of the roughly $201.2-$201.4 million analysts had penciled in; more damaging was the updated full-year revenue guidance, whose midpoint came in approximately 3.4% below prior Street estimates. On the earnings side, Collegium delivered adjusted EPS of $1.92, comfortably ahead of the consensus around $1.72, and adjusted EBITDA of $113.8 million also beat expectations. However, the pain portfolio - which includes BELBUCA, Xtampza ER, and the Nucynta franchise - generated quarterly net revenues of $140.9 million, reflecting ongoing headwinds from generic competition that have weighed on the segment. JORNAY PM continued its rapid ascent, rising 41% year-over-year to $46.1 million, and the newly acquired AZSTARYS contributed $12.9 million for a partial quarter following the $650 million acquisition completed in May, but these positives could not offset the market's reaction to the guidance cut. From a broader market perspective, the NASDAQ composite was modestly in the red on the day, providing a slightly unfavorable backdrop for growth-oriented healthcare names, though the index-level decline was far smaller than COLL's pre-market drop. The S&P 500 was essentially unchanged, suggesting the sell-off was driven almost entirely by company-specific factors rather than any macro or sector-wide event. -6.02 (-16.84%) Real-time Data · 15:16:48 · USD Taken together, the combination of a top-line miss, a meaningful downward revision to the full-year revenue outlook, and lingering concerns about the durability of the pain portfolio proved too much for investors to absorb, pushing the stock toward its 52-week low of $30.13 - effectively erasing the gains accumulated since the AZSTARYS acquisition was announced. Is your COLL trade worth the risk? Before you click "buy," know exactly where to set your stop-loss. Our Vision AI literally "sees" your COLL chart and delivers a complete risk management plan - entry, stop-loss, and profit target - in under 60 seconds. Protect your downside. Validate every trade. Invest smarter.
Collegium Pharmaceutical reported Q2 2026 revenue of $199.9 million, missing analyst estimates of $201.2 million but representing 6.3% year-on-year growth. The company's stock fell following the announcement. The pharmaceutical firm's full-year revenue guidance of $840 million came in 3.4% below analyst expectations. However, Collegium beat earnings estimates with non-GAAP profit of $1.92 per share, 8.8% above consensus. The company completed its acquisition of AZSTARYS and reported 41% revenue growth in its ADHD portfolio. Operating margin declined to 1.9% from 18.7% in the same quarter last year. EBITDA guidance of $457.5 million at midpoint fell short of analyst estimates of $482.8 million. Over the past five years, Collegium has grown sales at 19.9% annually, though recent two-year growth has moderated to 18.4%.
Collegium Pharmaceutical reported second quarter 2026 net revenues of $199.9 million, up 6% year-over-year. The company completed its acquisition of AZSTARYS in May, strengthening its ADHD portfolio. JORNAY PM generated $46.1 million in quarterly revenue, up 41% year-over-year, whilst AZSTARYS contributed $12.9 million from May 12 onwards. The pain portfolio produced $140.9 million in revenues, down 9% year-over-year. The company updated its full-year 2026 guidance, lowering product revenue expectations to $825-855 million from $865-895 million, primarily due to lower pricing on Nucynta generic versions. AZSTARYS revenue guidance increased to $65-75 million from $60-70 million. Collegium generated $71.3 million in operating cash flow during the quarter and ended with $129.5 million in cash and marketable securities.
Settlements made to be broken? (Part 1). When an ANDA filer settles its PIV case with the brand company, they expect to have certainty as to how the parties proceed from there. In fact, the settlement should bring at least some certainty as to launch date into the PIV Market. But two recent cases suggest that maybe how the settlement plays out is not really according to plan. Perhaps settlements are more fragile than what they seem to be. Development License Agreement. This story is common in the PIV Market: * (1) A company (in this case Grünenthal) invents a patent(s) for a pharmaceutical product (Nucynta(R) ER(tapentadol)); * (2) Grünenthal prefers to license its patents and product to a US based firm (Janssen) and they execute a License Agreement in 2003; * (3) Instead of Grünenthal, Janssen brings the product to market and sells it, profiting both Janssen and Grünenthal; * (4) Years later, in 2015, Janssen sheds the product from its portfolio to Depomed by selling the License Agreement (who in turns sells it to Collegium) with the blessing of Grünenthal. * Collegium "runs the product" for its waning years at the end of its product's life cycle while sending along royalty payments to Grünenthal. What is also a common story in the PIV Market: After a PIV cases have been filed, years of litigation, and continued anxiety for all parties, parties typically settle their cases. One of these settlement agreements may come in the form of an Authorized Generic Agreement. In this case, Collegium entered into such an Agreement with Hikma in 2024. Authorized Generics have been around for 20+ years - the idea is that the brand company authorizes one generic company as a partner. The generic company sells the product as a generic and sends along some royalties to the brand company. Without them, brand companies would get nothing from the generic market, and, in their eyes, something is better than nothing. Sometimes, it means that the brand company simply repackages its own brand as a generic to sell it as a generic. Under this Agreement, Hikma becomes an authorized distributor of the generic form of (Nucynta(R) ER(tapentadol). No one told Grünenthal. While not completely clear whether Grünenthal knew about the Authorized Generic Agreement, it apparently learned of an imminent launch of the generic of tapentadol when Collegium and Hikma issued a joint press release touting their partnership and its imminent launch. This Agreement has not set well with Grünenthal. Shortly after the press release, Grünenthal filed a patent infringement suit against Collegium and Hikma. They seek to protect their two Orange Book patents which expire in 2028-2029. Of course, though ParagraphFour don't know the private conversations among these three companies, but it does beg the questions regarding communication amongst them. The suit makes it clear that Grünenthal believes its patents are still valid and hasn't given up on them.